This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) (UVA-Gen001)

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by William Petersen, MD, University of Virginia
Sponsor:
Information provided by (Responsible Party):
William Petersen, MD, University of Virginia
ClinicalTrials.gov Identifier:
NCT02624388
First received: October 27, 2015
Last updated: June 20, 2017
Last verified: June 2017
  Purpose
Toxicities related to pediatric cancer treatment can lead to significant illness, organ damage, treatment delays, increased health care cost, and decrease in quality of life. Such toxicities are largely due to tissue damage sustained by chemotherapy, and strategies designed to limit such cellular damage to normal tissues may reduce therapy-related morbidity and mortality. In addition to their in vitro and in vivo anti-cancer effects, naturally occurring soy isoflavones have anti-inflammatory and anti-oxidant properties, and have been shown to reduce side effects of therapy in adult oncology clinical trials. This study will examine the effect of genistein, the major isoflavone component in soybeans and the most extensively studied of the soy isoflavones, on short-term side effects of myelosuppressive chemotherapy in pediatric cancer patients. Subjects will be randomized to receive either: a) 30 mg genistein daily throughout chemotherapy Cycles 1 and 2 and placebo during chemotherapy Cycles 3 and 4; or b) placebo daily during chemotherapy Cycles 1 and 2 and 30 mg genistein daily during chemotherapy Cycles 3 and 4. Investigators hypothesize that subjects will have fewer short-term therapy-related side effects during cycles of chemotherapy given in conjunction with genistein supplementation than cycles given with placebo.

Condition Intervention Phase
Lymphoma Childhood Lymphoma Solid Tumor Childhood Solid Tumor Neuroblastoma Ewing Sarcoma Hodgkin Lymphoma Non-Hodgkin Lymphoma Rhabdomyosarcoma Soft Tissue Sarcoma Medulloblastoma Germ Cell Tumor Wilms Tumor Brain Neoplasms Medulloblastoma, Childhood Neuroectodermal Tumors, Primitive Drug: Genistein Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Participant, Care Provider, Investigator
Primary Purpose: Supportive Care
Official Title: A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive Chemotherapy

Resource links provided by NLM:


Further study details as provided by William Petersen, MD, University of Virginia:

Primary Outcome Measures:
  • Time to neutrophil count recovery following myelosuppressive chemotherapy [ Time Frame: From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays ]

Secondary Outcome Measures:
  • Serum marker levels of inflammation during cycles of chemotherapy [ Time Frame: Once before treatment starts and then four more times while the study drug is being taken, an 8 - 16 week period if there are no chemotherapy delays ]
  • Number of days that participants experience adverse events that are commonly caused by chemotherapy treatment [ Time Frame: From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays ]
  • Number of participants who experience adverse events that are commonly caused by chemotherapy treatment [ Time Frame: From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays ]
  • Number of times per participant that adverse events that are commonly caused by chemotherapy treatment occur [ Time Frame: From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays ]
  • Severity of adverse events that are commonly caused by chemotherapy treatment [ Time Frame: From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays ]
  • Number of days that participants are hospitalized or have prolonged hospitalization due to an adverse event [ Time Frame: From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays ]
  • Number of days that planned cancer treatment is delayed due to an adverse event [ Time Frame: From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays ]
  • Percent that planned cancer treatment doses are reduced due to an adverse event [ Time Frame: From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays ]
  • Number of days that antimicrobial treatment is administered [ Time Frame: From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays ]
  • Number of participants who are administered granulocyte-colony stimulating factor (G-CSF) [ Time Frame: From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays ]
  • Number of times per participant that granulocyte-colony stimulating factor (G-CSF) is administered [ Time Frame: From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays ]
  • Number of participants who are administered a blood product [ Time Frame: From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays ]
  • Number of times per participant that a blood product is administered [ Time Frame: From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays ]
  • Number of times that a blood product is administered for anemia, decreased platelets, abnormal bleeding, or the subject's best interest [ Time Frame: From the first date study drug is taken until the last date that study drug is taken, about 8 - 12 weeks if there are no chemotherapy delays ]

Estimated Enrollment: 50
Study Start Date: August 2016
Estimated Study Completion Date: June 2019
Estimated Primary Completion Date: August 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A: Genistein followed by Placebo
Genistein daily throughout chemotherapy cycles 1 and 2, and placebo daily during chemotherapy cycles 3 and 4
Drug: Genistein
Estrogen-like compound (isoflavone) derived from soybeans
Other Names:
  • 5, 7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one
  • i-cool tablets containing 30 mg geniVida™
Drug: Placebo
Pill that contains no medicine
Experimental: Arm B: Placebo followed by Genistein
Placebo daily throughout chemotherapy cycles 1 and 2, and genistein daily during chemotherapy cycles 3 and 4
Drug: Genistein
Estrogen-like compound (isoflavone) derived from soybeans
Other Names:
  • 5, 7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one
  • i-cool tablets containing 30 mg geniVida™
Drug: Placebo
Pill that contains no medicine

Detailed Description:

This is a multi-center, randomized, double blind, placebo-controlled crossover study to evaluate the effect of soy isoflavones on the short term untoward effects of myelosuppressive chemotherapy used to treat pediatric cancers. Newly diagnosed cancer patients aged 1-21 years will be registered to the study and informed consent will be obtained prior to any study-related procedures. Stratification will be based on length of chemotherapy cycles, between 14 day and 21 day cycles. Within strata registered subjects will be randomized 1:1 to one of two schedules:

Arm A: Subjects will receive genistein daily throughout chemotherapy cycles 1 and 2, and placebo during chemotherapy cycles 3 and 4

Arm B: Subjects will receive placebo daily throughout chemotherapy cycles 1 and 2, and genistein during chemotherapy cycles 3 and 4

Subjects will be assessed for safety and efficacy during each cycle with clinical labs, cytokine panels, and physical exams. Drug compliance will be monitored by use of a patient diary as well as monitoring of serum genistein levels. Adverse events will be monitored starting on Cycle 1 Day 1 through 30 days following the last day of protocol therapy (genistein/placebo).

  Eligibility

Ages Eligible for Study:   1 Year to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Newly diagnosed solid tumor or lymphoma with histological verification
  2. Age 1 - 21 years at time of diagnosis
  3. Karnofsky/Lanksy performance score of ≥ 50
  4. Able to tolerate enteral medication administration
  5. Planned chemotherapeutic regimen for a patient must meet all of the following criteria:

    • A known myelosuppressive regimen which includes at least two of the following agents: actinomycin, carboplatin, cisplatin, cyclophosphamide, daunorubicin, doxorubicin, etoposide, ifosfamide, topotecan
    • At least four consecutive cycles
    • Cycle length is either 14 or 21 days
    • Regimen must either alternate myelosuppressive chemotherapeutic agents in an X-Y-X-Y format, such that the same chemotherapy is given every other cycle (e.g. vincristine/doxorubicin/cyclophosphamide │ ifosfamide/etoposide), or repeat the same chemotherapeutic agents each cycle in an X-X-X-X format (e.g. repeated cycles of cisplatin/etoposide/bleomycin). Courses eligible for this trial may occur at any time during treatment provided that they are consecutive and follow the one of the described patterns. Non-myelosuppressive anti-neoplastic treatments will not be considered for the purposes of determining eligibility. Questions regarding whether or not a patient's chemotherapy plan meets inclusion criteria will be decided by the Study Chair.
  6. Informed consent or parental permission and assent obtained prior to trial-related activities
  7. Able and willing to comply with all study related procedures
  8. Women of childbearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately

Exclusion Criteria

  1. Known allergy to soy or any soy-based food or supplement
  2. Unable or unwilling to discontinue consuming prohibited soy-based food or supplements while participating in this study
  3. Pre-existing neutropenia or neutrophil qualitative or quantitative disorder
  4. Pre-existing cytopenia or bone marrow failure syndrome
  5. History of gastric or duodenal ulcers or hyperacidity syndromes
  6. History of Human Immunodeficiency Virus (HIV)
  7. Has an active infection requiring systemic therapy
  8. Planned treatment does not include myelosuppressive chemotherapy
  9. Enrolled on a therapeutic or supportive care clinical trial within the last 30 days
  10. Current acute or chronic leukemia diagnosis
  11. Requires medication dosing via an enteral feeding tube that terminates in the duodenum or jejunum. (Enteral feeding tubes that terminate in the stomach are acceptable for study medication delivery.)
  12. Pregnant or breastfeeding woman
  13. Incarceration
  14. Secondary malignancy, i.e. the cancer for which the patient is presently or will be receiving treatment may not be a malignancy related to prior cancer therapy
  15. Any condition which might be worsened by estrogen, such as breast cancer, uterine cancer, ovarian cancer, endometriosis or uterine fibroids
  16. Any condition, in the investigator's opinion, that would compromise patient safety or study outcomes
  17. Anyone who, in the investigator's discretion, would be unwilling or unable to comply with study procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02624388

Contacts
Contact: William C. Petersen, Jr., M.D. 434-924-5105 wcp3g@virginia.edu
Contact: Cynthia Fischer, C.C.R.C. 434-243-0910 crb3y@virginia.edu

Locations
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Cynthia Fischer, C.C.R.C.    434-243-0910    crb3y@virginia.edu   
Contact: Candace Hudspeth, C.C.R.C.    434-982-1091    ckh3k@virginia.edu   
Principal Investigator: William C Petersen, Jr., M.D.         
Sponsors and Collaborators
University of Virginia
Investigators
Principal Investigator: William C. Petersen, Jr., M.D. University of Virginia
  More Information

Responsible Party: William Petersen, MD, Director, Pediatric Novel Therapeutics Program (Hematology/Oncology), University of Virginia
ClinicalTrials.gov Identifier: NCT02624388     History of Changes
Other Study ID Numbers: 17588
Study First Received: October 27, 2015
Last Updated: June 20, 2017

Keywords provided by William Petersen, MD, University of Virginia:
Genistein
Soy
Chemotherapy side-effects
Pediatric Cancer
Isoflavone

Additional relevant MeSH terms:
Lymphoma
Neoplasms
Sarcoma
Lymphoma, Non-Hodgkin
Hodgkin Disease
Neuroblastoma
Neoplasms, Germ Cell and Embryonal
Rhabdomyosarcoma
Wilms Tumor
Sarcoma, Ewing
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Medulloblastoma
Brain Neoplasms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms, Connective and Soft Tissue
Neuroectodermal Tumors, Primitive, Peripheral
Neoplasms, Neuroepithelial
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Myosarcoma
Neoplasms, Muscle Tissue
Neoplasms, Complex and Mixed
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms

ClinicalTrials.gov processed this record on June 23, 2017